← Leaderboards
Bruce E Sands
Massachusetts General Hospital
$6,502,130
Attributed
$9,668,207
Total exposure
13
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$9,668,207 · 12
FDA$0 · 1
By mechanism
U01$4,749,115 · 1
M01$2,247,802 · 6
T32$907,500 · 1
K23$649,405 · 1
P30$581,135 · 1
R21$447,750 · 1
Top collaborators
- Ashish Atreja4 shared
- Maged Rizk3 shared
- Miguel D Regueiro1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Lea K Davis$7,633,493
- Jane M Murphy$2,094,409
- Abrar A Qureshi$2,487,735
- Stephen B. Calderwood$9,897,507
- Kendra Elizabeth Wulczyn$329,778
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchInflammatory Bowel DiseasesHuman SubjectClinical TrialsCrohn'S DiseaseHuman Therapy EvaluationS DiseaseFundingResourcesResearch PersonnelBaseTranslatingDesignLaboratoriesDisorder ControlResearch DesignClinical Trial Phase IClinicGastrointestinal Disorder ChemotherapyCrohn&AposImmunotherapyGeneticAffectEnvironmental Risk Factor
Grant awards (44)
Translating Scientific Evidence into Practice using Digital Medicine and Electronic Patient Reported Outcomes$1,192,712
U01 · FY2023 · TR · contact PI
Translating Scientific Evidence into Practice using Digital Medicine and Electronic Patient Reported Outcomes$1,197,410
U01 · FY2022 · TR · contact PI
Translating Scientific Evidence into Practice using Digital Medicine and Electronic Patient Reported Outcomes$1,147,027
U01 · FY2021 · TR · contact PI
Translating Scientific Evidence into Practice using Digital Medicine and Electronic Patient Reported Outcomes$1,211,966
U01 · FY2020 · TR · contact PI
CLINICAL/TISSUE CORE$122,595
P30 · FY2015 · DK · contact PI
CLINICAL/TISSUE CORE$122,594
P30 · FY2014 · DK · contact PI
CLINICAL/TISSUE CORE$92,982
P30 · FY2013 · DK · contact PI
CLINICAL/TISSUE CORE$123,912
P30 · FY2012 · DK · contact PI
CLINICAL/TISSUE CORE$119,052
P30 · FY2011 · DK · contact PI
Research Training in Digestive Diseases$398,255
T32 · FY2009 · DK · contact PI
Research Training in Digestive Diseases$60,815
T32 · FY2009 · DK · contact PI
Research Training in Digestive Diseases$448,430
T32 · FY2008 · DK · contact PI
OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo$133,404
R21 · FY2008 · DK · contact PI
OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo$99,346
R21 · FY2008 · DK · contact PI
OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo$215,000
R21 · FY2007 · DK · contact PI
PROSPECTIVE DEVELOPMENT AND EVALUATION OF A BIOMARKER INDEX FOR MONITORING CROHN$5,465
M01 · FY2007 · RR · contact PI
PROSPECTIVE DEVELOPMENT AND EVALUATION OF A BIOMARKER INDEX FOR MONITORING CROHN$18,071
M01 · FY2006 · RR · contact PI
IMURAN Dose Ranging Study in Crohn's Disease$0
R01 · FY2005 · FD
IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE$129,951
K23 · FY2004 · DK
IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE$129,951
K23 · FY2003 · DK
Hyperhomocysteinemia/Thrombosis Risk--Inflammatory Bowel$200,768
M01 · FY2002 · RR
MECHANISM OF ORAL TOLERANCE IN HEALTH &INFLAMMATORY BOWEL DISEASE$200,768
M01 · FY2002 · RR
MECHANISM OF ORAL TOLERANCE IN HEALTH &INFLAMMATORY BOWEL DISEASE$200,768
M01 · FY2002 · RR
TREATMENT WITH SUBCUTANEOUS RHUIL 10 IN STEROID DEPENDENT CROHNS DISEASE$200,768
M01 · FY2002 · RR
TREATMENT WITH SUBCUTANEOUS RHUIL 10 IN STEROID DEPENDENT CROHNS DISEASE$200,768
M01 · FY2002 · RR
Hyperhomocysteinemia/Thrombosis Risk--Inflammatory Bowel$200,768
M01 · FY2002 · RR
IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE$129,951
K23 · FY2002 · DK
TREATMENT WITH SUBCUTANEOUS RHUIL 10 IN STEROID DEPENDENT CROHNS DISEASE$200,768
M01 · FY2001 · RR
MECHANISM OF ORAL TOLERANCE IN HEALTH &INFLAMMATORY BOWEL DISEASE$200,768
M01 · FY2001 · RR
Hyperhomocysteinemia/Thrombosis Risk--Inflammatory Bowel$200,768
M01 · FY2001 · RR
IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE$129,951
K23 · FY2001 · DK
MECHANISM OF ORAL TOLERANCE IN HEALTH &INFLAMMATORY BOWEL DISEASE$0
M01 · FY2001 · RR
Hyperhomocysteinemia/Thrombosis Risk--Inflammatory Bowel$0
M01 · FY2001 · RR
TREATMENT WITH SUBCUTANEOUS RHUIL 10 IN STEROID DEPENDENT CROHNS DISEASE$0
M01 · FY2001 · RR
CLINICAL TRIAL OF RECOMB HUMAN INTERLEUKIN ELEVEN (RHIL-11) IN CROHN'S DISEASE$415,629
M01 · FY2000 · RR
IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE$129,601
K23 · FY2000 · DK
PILOT STUDY FOR A 'NEW ONSET CROHN'S INTERVENTION STUDY'$85,500
R03 · FY2000 · DK
CLINICAL TRIAL OF RECOMB HUMAN INTERLEUKIN ELEVEN (RHIL-11) IN CROHN'S DISEASE$575
M01 · FY2000 · RR
TREATMENT WITH SUBCUTANEOUS RHUIL 10 IN STEROID DEPENDENT CROHNS DISEASE$575
M01 · FY2000 · RR
MECHANISM OF ORAL TOLERANCE IN HEALTH &INFLAMMATORY BOWEL DISEASE$575
M01 · FY2000 · RR
Hyperhomocysteinemia/Thrombosis Risk--Inflammatory Bowel$0
M01 · FY2000 · RR
Hyperhomocysteinemia/Thrombosis Risk--Inflammatory Bowel$0
M01 · FY2000 · RR
TREATMENT WITH SUBCUTANEOUS RHUIL 10 IN STEROID DEPENDENT CROHNS DISEASE$0
M01 · FY2000 · RR
MECHANISM OF ORAL TOLERANCE IN HEALTH &INFLAMMATORY BOWEL DISEASE$0
M01 · FY2000 · RR